REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Tissue Regeneration Complex

Recovery & Healingadvanced
27
Share
Peptides

4

Avg Daily mcg

3,371

Level

advanced

Added

May 16, 2026

Overview

The Tissue Regeneration Complex is an advanced-level protocol that combines four potent peptides to create the most comprehensive tissue repair stack available. Designed for serious injuries, post-surgical recovery, or chronic degenerative conditions that have not responded to simpler interventions, this stack recruits every major pathway involved in tissue regeneration: angiogenesis, cellular migration, immune modulation, extracellular matrix remodeling, and growth factor amplification. BPC-157 at 500mcg twice daily provides the highest therapeutic dose of this gastric pentadecapeptide, ensuring maximum local tissue repair signaling. At this dosing frequency, BPC-157 maintains continuous activation of VEGF receptors, nitric oxide pathways, and growth hormone receptor upregulation at injury sites. The twice-daily protocol is particularly important for severe injuries where the repair demand exceeds what single daily dosing can support. Research has shown dose-dependent improvements in tendon, muscle, and organ tissue healing with BPC-157. TB-500 at 5000mcg twice weekly delivers a robust systemic healing signal through Thymosin Beta-4 pathway activation. This higher dose promotes aggressive cellular migration via actin upregulation, reduces inflammatory cytokine expression, and creates a whole-body environment conducive to repair. The systemic distribution of TB-500 ensures that even deep or diffuse tissue damage receives regenerative signaling regardless of injection location. GHK-Cu at 300mcg daily adds copper-peptide-mediated tissue remodeling to the protocol. This tripeptide activates genes involved in collagen synthesis, nerve regeneration, and antioxidant enzyme production. It helps ensure that regenerating tissue develops proper structural organization rather than disorganized scar tissue, resulting in more functional healing outcomes. Thymosin Alpha-1 at 1500mcg three times weekly provides critical immune system optimization during the recovery process. Healing tissues are vulnerable to infection, and the immune system plays an essential role in debris clearance and growth factor production. Thymosin Alpha-1 enhances macrophage function, improves T-cell mediated surveillance of healing tissues, and prevents immune suppression that can accompany major tissue trauma. This protocol is suited for individuals recovering from major surgeries, severe sports injuries, or multi-site trauma. It is also appropriate for chronic conditions like degenerative disc disease or advanced tendinopathy. Recommended cycle length is 8-12 weeks with regular monitoring. Due to the advanced nature and multiple compounds involved, prior experience with simpler peptide protocols is strongly recommended before undertaking this stack.

Dosing Protocol

BPC-157

Twice per day

Read more about BPC-157 →

500 mcg

per dose

TB-500

Twice per week

Read more about TB-500 →

5,000 mcg

per dose

300 mcg

per dose

Thymosin Alpha-1

3 times per week

Read more about Thymosin Alpha-1 →

1,500 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.